Next-generation "armored" CAR T cell therapy shows promising results in lymphoma patients

Enhanced CAR T cell therapy offers new strategy for lymphoma

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

Next-generation "armored" CAR T cell therapy shows promising results in lymphoma patients

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies.

'Armored' CAR T Cells Highly Active in Lymphoma After Prior CAR-T Failure

(MedPage Today) -- A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I trial of lymphoma patients who had previously failed anti-CD19 CAR T-cell therapy. Among 21 patients...

Exploring the Treatment Options for RRMM

Panelists discuss how treatment selection for relapsed/refractory multiple myeloma hinges on the pace of disease progression, with options ranging from second autologous transplants to chimeric antigen receptor T-cell therapies and bispecific antibodies, each tailored to patient status, prior therapy, and urgency of intervention.

Penn Medicine’s ‘Armored’ CAR-T Cell Therapy Shows Early Success Against Relapsed/Refractory B-Cell Lymphoma

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Since then, six additional CAR-T cell therapies have been introduced to the market. Four of the seven are approved for B-cell lymphomas.

Armored CAR T Therapy Shows Promise for Relapsed Lymphoma

A new generation of CAR T-cell therapy has shown encouraging results in patients with relapsed or refractory B-cell lymphoma who had previously failed standard treatments, including existing CAR T therapies. In a Phase I trial published in The New England Journal of Medicine, researchers at the University of Pennsylvania tested huCART19-IL18—a novel “armored” CAR T therapy designed to overcome tumor-induced immune suppression by secreting interl…